Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLoans - Loss AllowanceNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Current Leases: 2019-2024

  • RedHill Biopharma's Current Leases fell 50.84% to $353,000 in Q4 2024 from the same period last year, while for Dec 2024 it was $353,000, marking a year-over-year decrease of 50.84%. This contributed to the annual value of $353,000 for FY2024, which is 50.84% down from last year.
  • RedHill Biopharma's Current Leases amounted to $353,000 in Q4 2024, which was down 50.84% from $718,000 recorded in Q4 2023.
  • Over the past 5 years, RedHill Biopharma's Current Leases peaked at $1.7 million during Q4 2020, and registered a low of $353,000 during Q4 2024.
  • In the last 3 years, RedHill Biopharma's Current Leases had a median value of $718,000 in 2023 and averaged $701,000.
  • In the last 5 years, RedHill Biopharma's Current Leases surged by 105.04% in 2020 and then plummeted by 50.84% in 2024.
  • Over the past 5 years, RedHill Biopharma's Current Leases (Quarterly) stood at $1.7 million in 2020, then dropped by 5.38% to $1.6 million in 2021, then tumbled by 36.22% to $1.0 million in 2022, then slumped by 30.43% to $718,000 in 2023, then slumped by 50.84% to $353,000 in 2024.
  • Its Current Leases was $353,000 in Q4 2024, compared to $718,000 in Q4 2023 and $1.0 million in Q4 2022.